Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Temsirolimus

FDA-approved product (solution, intravenous), marketed as Temsirolimus, Torisel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Temsirolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Clear cell renal carcinoma
  • Mantle cell lymphoma
  • Neoplasm
  • Renal cell carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Mammalian target of rapamycin (mtor) kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA70.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Temsirolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Temsirolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

    NCT01369433 · start 2010-06

    Registered record
    Registry ID
    NCT01369433
    Conditions
    Solid Tumors
    Interventions
    Tivozanib + paclitaxel; Tivozanib + temsirolimus; Tivozanib; Tivozanib (AV-951); Tivozanib + capecitabine; Tivo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2010-06
    Completion
    2015-10
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionTivozanib + paclitaxel; Tivozanib + temsirolimus; Tivozanib; Tivozanib (AV-951) +2 more
    PhaseNot applicable
    Registry statusTerminated

  • Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

    NCT01015664 · start 2010-02

    Registered record
    Registry ID
    NCT01015664
    Conditions
    Squamous Cell Carcinoma of the Head and Neck
    Interventions
    temsirolimus; cisplatin; cetuximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2010-02
    Completion
    2012-12
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSquamous Cell Carcinoma of the Head and Neck
    Interventiontemsirolimus; cisplatin; cetuximab
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Sirolimus as Therapeutic Approach to Uveitis

    NCT00908466 · start 2009-07

    Registered record
    Registry ID
    NCT00908466
    Conditions
    Uveitis; Intermediate Uveitis; Posterior Uveitis; Panuveitis
    Interventions
    Sirolimus (rapamycin); Sirolimus (rapamycin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-07
    Completion
    2013-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUveitis; Intermediate Uveitis; Posterior Uveitis; Panuveitis
    InterventionSirolimus (rapamycin); Sirolimus (rapamycin)
    PhasePhase 1
    Registry statusCompleted

  • Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma

    NCT00942747 · start 2009-07

    Registered record
    Registry ID
    NCT00942747
    Conditions
    Recurrent or Refractory Primary CNS Lymphoma
    Interventions
    temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2009-07
    Completion
    2014-06
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent or Refractory Primary CNS Lymphoma
    Interventiontemsirolimus
    PhasePhase 2
    Registry statusUnknown

  • Polycystic Liver Disease in Kidney Transplant

    NCT00934791 · start 2009-02

    Registered record
    Registry ID
    NCT00934791
    Conditions
    Polycystic Liver Disease
    Interventions
    Tacrolimus; Sirolimus; Mycophenolate Mofetil; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2009-02
    Completion
    2012-12
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Liver Disease
    InterventionTacrolimus; Sirolimus; Mycophenolate Mofetil; Prednisone
    PhaseNot applicable
    Registry statusTerminated

  • Prospective Study of Rapamycin for the Treatment of SLE

    NCT00779194 · start 2008-10

    Registered record
    Registry ID
    NCT00779194
    Conditions
    Systemic Lupus Erythematosus (SLE)
    Interventions
    Rapamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-10
    Completion
    2015-12-16
    Enrolment
    99

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Lupus Erythematosus (SLE)
    InterventionRapamycin
    PhasePhase 2
    Registry statusCompleted

  • Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma

    NCT01404104 · start 2008-09

    Registered record
    Registry ID
    NCT01404104
    Conditions
    Renal Cell Carcinoma
    Interventions
    Temsirolimus (pre surgery)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-09
    Completion
    2014-08
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma
    InterventionTemsirolimus (pre surgery)
    PhaseNot applicable
    Registry statusCompleted

  • Doxil, Bevacizumab and Temsirolimus Trial

    NCT00761644 · start 2008-08-21

    Registered record
    Registry ID
    NCT00761644
    Conditions
    Advanced Cancer
    Interventions
    Doxil; Bevacizumab; Temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-08-21
    Completion
    2019-03-28
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer
    InterventionDoxil; Bevacizumab; Temsirolimus
    PhasePhase 1
    Registry statusCompleted

  • Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex

    NCT00411619 · start 2007-01

    Registered record
    Registry ID
    NCT00411619
    Conditions
    Tuberous Sclerosis; Subependymal Giant Cell Astrocytoma
    Interventions
    Everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2007-01
    Completion
    2014-01
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberous Sclerosis; Subependymal Giant Cell Astrocytoma
    InterventionEverolimus
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

    NCT00467194 · start 2006-12

    Registered record
    Registry ID
    NCT00467194
    Conditions
    Liver Cancer
    Interventions
    Rapamycin; Bevacizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-12
    Completion
    Not recorded
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cancer
    InterventionRapamycin; Bevacizumab
    PhasePhase 1
    Registry statusCompleted

  • Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

    NCT00335764 · start 2006-04

    Registered record
    Registry ID
    NCT00335764
    Conditions
    Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
    Interventions
    sorafenib tosylate; erlotinib hydrochloride; tipifarnib; temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2006-04
    Completion
    2012-09
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
    Interventionsorafenib tosylate; erlotinib hydrochloride; tipifarnib; temsirolimus
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents

    NCT00552669 · start 2006-01

    Registered record
    Registry ID
    NCT00552669
    Conditions
    Coronary Heart Disease; Coronary Restenosis
    Interventions
    Oral sirolimus; Drug Eluting stent
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-01
    Completion
    2007-09
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Heart Disease; Coronary Restenosis
    InterventionOral sirolimus; Drug Eluting stent
    PhasePhase 4
    Registry statusCompleted

  • Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)

    NCT00795886 · start 2005-08

    Registered record
    Registry ID
    NCT00795886
    Conditions
    Acute Lymphoblastic Leukemia
    Interventions
    RAPAMYCIN
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-08
    Completion
    2010-03
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia
    InterventionRAPAMYCIN
    PhasePhase 2
    Registry statusCompleted

  • A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

    NCT00166712 · start 2005-04

    Registered record
    Registry ID
    NCT00166712
    Conditions
    Kidney Transplant Failure and Rejection
    Interventions
    Tacrolimus (TAC); Sirolimus; Alemtuzumab; Mycophenolate mofetil (MMF)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2005-04
    Completion
    2010-04
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplant Failure and Rejection
    InterventionTacrolimus (TAC); Sirolimus; Alemtuzumab; Mycophenolate mofetil (MMF)
    PhasePhase 4
    Registry statusTerminated

  • CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor

    NCT00087074 · start 2004-06

    Registered record
    Registry ID
    NCT00087074
    Conditions
    Gastrointestinal Stromal Tumor; Recurrent Adult Soft Tissue Sarcoma; Stage I Adult Soft Tissue Sarcoma; Stage II Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
    Interventions
    temsirolimus; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-06
    Completion
    Not recorded
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumor; Recurrent Adult Soft Tissue Sarcoma; Stage I Adult Soft Tissue Sarcoma; Stage II Adult Soft Tissue Sarcoma +2 more
    Interventiontemsirolimus; laboratory biomarker analysis
    PhasePhase 2
    Registry statusCompleted